Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first clinical trial of a gene therapy for an inherited cause of progressive blindness called choroideremia has shown very promising initial results, surpassing the expectations of the researchers involved.

Promising first results in gene therapy trial for inherited blindness Mr John Brett, Oxford Eye Hospital Photographic Department
University of Oxford surgeons Prof Robert MacLaren and Mr Markus Groppe are currently running the retinal gene therapy trial at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Trust

Professor Robert MacLaren of the Nuffield Laboratory of Ophthalmology (part of the Nuffield Department of Clinical Neurosciences) led the development of the retinal gene therapy and this first clinical trial.


Read article on BBC news...